However, they co-occur with mutations in important tumor suppressor genes, such as STK11 (also known as LKB1), KEAP1, TP53, or CDKN2A, whose inactivation cooperates with KRAS in the oncogenic process and, thus, characterize the heterogeneous nature of KRAS mutant tumors (12, 13). The gene discussed is STK11; the disease is neoplasm.